Press Release
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology. – INB-01 may enable direct-to-brain delivery of various compounds in development across atai’s
October 18, 2022
Press Release
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo. – Topline results, including Part 2 comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, are
October 12, 2022
Press Release
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) under development for treatment-resistant depression (TRD) in combination with atai’s digital
October 5, 2022
Press Release
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October:
October 4, 2022
Press Release
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
- atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers - EMP-01 is a
September 27, 2022
Press Release
atai Life Sciences to Participate in September Investor Events
NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17 th Annual
September 6, 2022
Displaying 37 - 42 of 107